BlossomHill Therapeutics, Inc. (BLSM) stock price, financials & research

Regular session · ET · Market data may be delayed.

Company profile

Blossomhill Therapeutics, Inc. is a biopharmaceutical company. It engages in the development of small molecule medicines for unmet medical needs in cancer treatment. The company was founded in June 2020 and is headquartered in San Diego, CA.

Industry: Biotechnology
Sector: Healthcare
Headquarters: US
CEO: Jing Rong Jean Cui
Listed since: Aug 7, 2026
Employees: 63

Market position

Day range

Current $25.74

$25.43$27.55

52-week range

Current $25.74

$15.25$27.80

Open: $26.80
Previous close: $26.82
Volume: 715.11K; 2.66× average
Average volume: 269.13K; Average daily volume
Market cap: 748.55M USD
Beta: 0; Market reference 1
50-day average: $19.3033; +33.34% above average
200-day average: $19.3033; +33.34% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value: 351.01M USD
P/E (TTM): -23.83×
P/B (TTM): -4.92×
P/S (TTM): 0×
EV / EBITDA: -5.52×
Earnings yield: -13.01%
Free cash flow yield: -10.31%
Dividend yield: 0.00%

Profitability & efficiency

Gross margin: 0.00%
Operating margin: 0.00%
Net margin: 0.00%
Return on equity: 45.97%
Return on assets: -37.16%
Return on invested capital: -43.41%

Financial health

Debt / equity: -0.15×
Current ratio: 8.97×

Financial statements

Income trends

Operating income

−64.02M USD-75.89%

Net income

−60.56M USD-97.28%

Financial statements: Income statement
Metric (USD)	FY2025	FY2024
Research and development	56.14M USD	31.81M USD
Selling, general, and administrative	7.89M USD	4.59M USD
Operating expenses	64.02M USD	36.4M USD
Interest income	3.48M USD	5.71M USD
Depreciation and amortization	441K USD	350K USD
Operating income	−64.02M USD	−36.4M USD
Net income	−60.56M USD	−30.7M USD

Company facts updated Sep 20, 2026.

Earnings

Latest fiscal-year EPS: -2.08; FY2025
Latest fiscal-year revenue: 0 USD; FY2025
Next fiscal-year EPS consensus: -3.86; FY2026 · 3 analysts

Annual EPS trend

Reported history and fiscal-year consensus

ReportedConsensus forecast

Annual revenue trend

Reported history and fiscal-year consensus

ReportedConsensus forecast

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$33.67

30.81% upside

Past 12 months12-month forecastHigh $36.00Average $33.67Low $30.00

BLSM news

globenewswire.comSep 18, 2026

BlossomHill Therapeutics Reports Second Quarter 2026 Financial Results

Strengthened balance sheet with successful completion of upsized $168.3 million initial public offering Announced FDA Fast Track designation for BH-30643 for the treatment of advanced EGFR C797S-positive NSCLC SAN DIEGO,…

Read source

globenewswire.comSep 15, 2026

BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of OMNI-EGFR™ Inhibitor BH-30643 in EGFR C797S-Positive NSCLC at IASLC 2026 World Conference on Lung Cancer

45% objective response rate and 88% disease control rate observed in patients with EGFR C797S-positive resistance to prior EGFR inhibitors, with or without concurrent T790M, a difficult-to-treat population with no…

Read source

defenseworld.netSep 9, 2026

BlossomHill Therapeutics, Inc.’s Quiet Period Set To Expire on September 16th (NASDAQ:BLSM)

BlossomHill Therapeutics' (NASDAQ: BLSM - Get Free Report) quiet period will end on Wednesday, September 16th. BlossomHill Therapeutics had issued 9,375,000 shares in its public offering on August 7th. The total size of…

Read source

globenewswire.comSep 3, 2026

BlossomHill Therapeutics to Present at the 8th Annual RAS-Targeted Drug Development Summit & H.C. Wainwright 28th Annual Global Investment Conference

SAN DIEGO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative…

Read source

globenewswire.comSep 1, 2026

BlossomHill Therapeutics to Present Updated Data from Ongoing Phase 1/2 SOLARA Trial of its Macrocyclic OMNI-EGFR™ Inhibitor, BH-30643, in EGFR-mutant NSCLC at the 2026 World Conference on Lung Cancer

Data to be presented in a mini-oral session will describe anti-tumor activity of BH-30643 in patients with secondary EGFR resistance mutations such as EGFR C797S BH-30643 was recently granted Fast Track designation by…

Read source

globenewswire.comAug 18, 2026

BlossomHill Therapeutics Announces FDA Fast Track Designation for BH-30643, a Macrocyclic OMNI-EGFR™ Inhibitor for the Treatment of Advanced EGFR C797S-positive NSCLC

SAN DIEGO, Aug. 18, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative…

Read source